News Release

Screening heart patients for depression not effective: McGill, Johns Hopkins study

American Heart Association call for routine screening 'premature' scientists say

Peer-Reviewed Publication

McGill University

This release is available in French.

In a study to be published in the Nov. 12 special edition of the Journal of the American Medical Association (JAMA), researchers at McGill University, Johns Hopkins University and six other institutions from around the world question the American Heart Association's recent suggestion that millions of North American cardiac patients be automatically screened for depression. Such screening would involve administering a questionnaire and other tests to try to identify individuals who might have had no history or clinical indications of depression but who may, nonetheless, be depressed.

The AHA maintains that the link between depression and cardiac care is important.

But Dr. Brett Thombs of McGill and the affiliated Jewish General Hospital, and Dr. Roy Ziegelstein, of Johns Hopkins, say there is not nearly enough medical evidence to support such a "massive, expensive and labour-intensive undertaking," and in fact provide evidence that testing for depression would not benefit patients in a cardiac care environment.

"It's a very appealing idea that non-mental health professionals can administer a quick, easy-to-use depression screening test, and that would somehow benefit patients," said Thombs, a psychologist and assistant professor in the Department of Psychiatry at McGill's Faculty of Medicine and at the JGH. "Unfortunately, the reality is that it would be an extremely difficult undertaking that wouldn't produce practical benefits for patients."

The study drew upon a collection of more than 1,500 clinical studies from around the world, of which 17 were selected for detailed review.

"We discovered that screening alone or screening and referral doesn't help most patients. This is true even in primary care where the doctor is usually better trained than a cardiologist to manage depression," said Thombs. "We see positive effects only in 'enhanced care' or 'collaborative care,' environments where they have mental-health specialists on call. And even there we only see tiny effects."

The researchers found that treating depression in people with heart disease only accounted for a 1 per cent to 4 per cent change in symptoms compared with those treated with placebo. This result, Ziegelstein said, is "too low to expect meaningful benefits for most people, particularly since screening methods are not very precise in identifying people who would benefit from the treatment."

"Moreover, we found no connection at all between getting treated for depression and cardiovascular outcomes, like having a subsequent heart attack," Thombs added. "That said, in no sense are we saying that depression doesn't matter. Depression leads to a great deal of suffering, cardiovascular effects aside, and it can definitely affect how well people take care of themselves after they've had a heart attack.

"We're just saying we don't have the tools in cardiovascular care settings to identify and improve the lives of people who aren't already being treated for depression. What we really need is more research on how best to help heart disease patients adopt healthy behaviours that combat depression, such as how to stop smoking, exercise regularly and maintain a healthy weight."

###

Other researchers who contributed to this study include Peter de Jonge, Ph.D., of the University Medical Center Groningen, Netherlands; James Coyne, Ph.D., of the University of Pennsylvania School of Medicine, in Philadelphia; Mary Whooley, M.D., of the University of California, San Francisco; Nancy Frasure-Smith, Ph.D., of McGill; Alex Mitchell, M.Sc., M.R.C. Psych, of the Leicester Royal Infirmary, UK; Marij Zuidersma, M.Sc., of Groningen; Cheri Smith, M.L.S., and Karl Soderlund, B.S., of Johns Hopkins, Chete Eze-Nliam, M.D., M.P.H., of Interfaith Medical Center in Brooklyn, N.Y.; and Bruno Lima, of the Federal University of Ceara School of Medicine, in Fontalez-ce, Brazil.

About McGill University

McGill University, founded in Montreal, Quebec in 1821, is Canada's leading post-secondary institution. It has two campuses, 11 faculties, 10 professional schools, 300 programs of study and more than 33,000 students. Since 2000, more than 800 professors have been recruited to McGill to share their energy, ideas and cutting-edge research. McGill attracts students from more than 160 countries around the world. Almost half of McGill students claim a first language other than English – including 6,000 francophones – with more than 6,200 international students making up almost 20 per cent of the student body.

About the JGH

Since 1934, the Sir Mortimer B. Davis - Jewish General Hospital, a McGill University teaching hospital, has provided "Care for All," serving patients from diverse religious, linguistic and cultural backgrounds in Montreal, throughout Quebec and beyond. As one of the province's largest acute-care hospitals, the JGH has achieved a reputation for excellence in key medical specialties by continually expanding and upgrading its facilities for clinical treatment and teaching, as well as research at the Lady Davis Institute for Medical Research. For more, please visit JGH.ca.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.